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for human epidermal growth factor receptor 2 (HER2) are treated with
HER2-targeted therapies such as trastuzumab, but limitations with
HER2 testing may lead to false-positive (FP) or false-negative (FN)
results. Objectives: To develop a US-level model to estimate the effect
of tumor misclassiﬁcation on health care costs and patient quality-
adjusted life-years (QALYs). Methods: Decision analysis was used to
estimate the number of patients with early-stage breast cancer (EBC)
whose HER2 status was misclassiﬁed in 2012. FP results were assumed
to generate unnecessary trastuzumab costs and unnecessary cases of
trastuzumab-related cardiotoxicity. FN results were assumed to save
money on trastuzumab, but with a loss of QALYs and greater risk of
disease recurrence and its associated costs. QALYs were valued at
$100,000 under a net monetary beneﬁt approach. Results: Among
226,870 women diagnosed with EBC in 2012, 3.12% (n ¼ 7,070) andee front matter Copyright & 2015, International S
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, Box 357630, Seattle, WA 98195.2.18% (n ¼ 4,955) were estimated to have had FP and FN test results,
respectively. Approximately 8400 QALYs (discounted, lifetime) were
lost among women not receiving trastuzumab because of FN results.
The estimated incremental per-patient lifetime burden of FP or FN
results was $58,900 and $116,000, respectively. The implied incremen-
tal losses to society were $417 million and $575 million, respectively.
Conclusions: HER2 tests result in misclassiﬁcation and nonoptimal
treatment of approximately 12,025 US patients with EBC annually. The
total economic societal loss of nearly $1 billion suggests that improve-
ments in HER2 testing accuracy are needed and that further clinical
and economic studies are warranted.
Keywords: breast cancer, economic burden, HER2 testing, trastuzumab.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
More than 200,000 women in the United States are diagnosed
with breast cancer each year [1]. Approximately 18% to 25% have
disease characterized by tumors that are considered to be human
epidermal growth factor receptor 2–positive, that is, overexpress-
ing the HER2 oncogene [2–5]. Tumor HER2 status is determined
using laboratory-based methods, such as immunohistochemistry
(IHC), ﬂuorescence in situ hybridization (FISH), and other in situ
hybridization methods. There is currently no gold standard for
HER2 testing [6]. Given the limitations inherent to available HER2
tests and variation in testing practices, some tumors may be
misclassiﬁed. With a false HER2-positive (FP) result, a patient’stumor is considered to be HER2-positive in the absence of HER2-
positive disease. With a false HER2-negative (FN) result, a
patient’s tumor is considered to be HER2-negative (i.e., having
normal HER2 levels) in the context of HER2-positive disease.
Given that HER2-positive breast cancer is associated with a
poorer prognosis than is HER2-negative disease, in the absence
of HER2 targeted therapy [2,7], and that HER2 status dictates
treatment course [8], the accurate determination of HER2 status is
clinically important.
Multiple studies have measured the rates of concordance and
discordance in HER2 status between central and local laboratories
[9–13]. Central laboratories may have advantages over local labora-
tories because they process a larger volume of specimens, participateociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 4 1 – 5 4 6542in continuous quality improvement, and periodically undergo quality
assessments [11]. The FP discordance rate is deﬁned as the proportion
of tumors classiﬁed as HER2-positive at a local laboratory but HER2-
negative at a central laboratory. The FN discordance rate is the
proportion of tumors found to be HER2-negative at a local laboratory
but HER2-positive at a central laboratory. In the VIRGO study, 552
tumor samples that were HER2-negative in local laboratories were
retested in a central laboratory [13]. A total of 22 were found to be
HER2-positive, resulting in an FN discordance rate of 4.0% [13]. FP
discordance rates as high as 20% have been reported [10–12].
The clinical and economic consequences of FP and FN test results
differ. FP results lead to the use of HER2-targeted therapy with little
chance of beneﬁt, resulting in an increased risk of treatment-
emergent adverse events and added treatment costs to the patient,
the payer, and/or the society. Conversely, FN results deny the patient
a potential net gain of 1.7 quality-adjusted life-years (QALYs), the
incremental QALYs associated with HER2-targeted therapy [14].
Moreover, patients with tumors misclassiﬁed as HER2-negative are
at an increased risk of disease recurrence, including progression to
metastatic breast cancer and its associated health care costs.
In the current analysis, we estimated the individual and
aggregate clinical and economic costs of HER2 testing inaccuracy
over the lifetime of the 2012 cohort of US women diagnosed with
early-stage breast cancer (EBC).Methods
Analytic Overview
The analysis used the net monetary beneﬁt approach to combine
aggregate direct medical care costs with the monetized value of
the QALYs lost. Probabilities of FP and FN test results were
obtained using decision-analytic modeling. The mean cost of FP
misclassiﬁcation was the sum of the added cost of trastuzumab,
the monetized disutility of cardiotoxicity (applied over 1 year),
and the added costs of treatment for trastuzumab-related car-
diotoxicity. The mean cost of FN test results was the sum of the
monetized QALYs lost because of missed trastuzumab treatment
plus additional recurrences minus the savings attributable to
trastuzumab-related costs (i.e., trastuzumab and the treatment of
trastuzumab-related cardiotoxicity). The probability and cost
data were used to calculate the costs of FP and FN misclassiﬁca-
tion and the total aggregate cost of HER2 test misclassiﬁcation.
Decision-Analytic Model
A decision-analytic model was developed to estimate 1) the
probability that a patient’s tumor HER2 status would be mis-
classiﬁed and 2) the associated health and economic consequen-
ces. The reference case was a patient with newly diagnosed
breast cancer whose tumor was tested for HER2 status. The
modeling framework classiﬁed patients into those whose tumors
were truly HER2-positive and those whose tumors were truly
HER2-negative (Fig. 1). Although technically unobservable, this
true status classiﬁcation was necessary to assess HER2 testing
accuracy and to estimate the expected proportion of misclassiﬁed
tumors. It was assumed that some patients’ tumors were initially
tested via IHC, whereas others were initially tested via FISH. For
patients whose tumors were modeled as having been initially
examined via IHC, individuals with tumor scores of IHC 3þ (based
on 10% intense membrane staining) were considered HER2-
positive and treated. Individuals with tumor scores of IHC 2þ
were considered equivocal and were retested using FISH, and
patients with FISH-positive tumors were treated. Patients with
tumor scores of IHC 1þ or IHC 0 were regarded as HER2-negative
and not treated. Of patients initially tested using FISH, thoseconsidered FISH-positive (HER2:CEP17 ratio Z2) were treated,
whereas those who were FISH-negative (HER2:CEP17 ratio o2)
were not. Patients were then categorized as having truly HER2-
positive (TP), truly HER2-negative (TN), FP, or FN tumors.
Probabilities and Costs
Data on probabilities and costs used in the model are presented in
Table 1. The model assumes near-perfect sensitivity and speciﬁcity
for FISH. The model also assumes a binomial IHC test proﬁle (for
purposes of estimating test accuracy at initial testing) by classifying
tumors with IHC 3þ scores as HER2-positive and tumors with IHC 0,
IHC 1þ, and IHC 2þ scores as HER2-negative. We assumed that the
reported sensitivity of IHC applied to a score of IHC 3þ. We then
used empirical estimates to distribute the complement (1 – sensi-
tivity) among patients with test scores of IHC 0, IHC 1þ, and IHC 2þ.
We similarly assumed that the speciﬁcity of IHC applied to com-
bined scores of IHC 0, IHC 1þ, and IHC 2þ. We then used empirical
estimates to derive the distribution of individual IHC results.
The costs of FP and FN test results included the costs of 1) IHC
and FISH testing, 2) chemotherapy, 3) trastuzumab, and 4) treating
trastuzumab-associated cardiotoxicity and 5) the additional cost
of disease recurrence for patients with tumors misclassiﬁed as FN
(Table 1). The costs associated with trastuzumab included current
drug costs, administration costs, left ventricular ejection fraction
assessment costs, and the physician follow-up costs. The added
costs of disease recurrence were estimated by multiplying the
incremental number of averted disease recurrences due to tras-
tuzumab among patients with HER2-positive EBC (based on a joint
B-31/N-9831 analysis that spanned 5 years) by the discounted
annual incremental cost of disease recurrence (based on cost-of-
illness methods) [15]; costs were then inﬂated to 2012 values.
Health Outcomes
The effect of tumor misclassiﬁcation on health outcomes was
divided into the QALYs lost because of FN test results and the
QALYs lost because of the added risk of trastuzumab-related
cardiotoxicity following FP test results. The estimate for dis-
counted, lifetime QALYs gained with or without trastuzumab
treatment was obtained from a previous cost-effectiveness anal-
ysis of EBC [14]. The utility of symptomatic cardiac events on
adjuvant therapy has been estimated to be 0.64 [16]. This value
was multiplied by the differential rate of symptomatic cardiac
complications among patients receiving treatment with pacli-
taxel plus trastuzumab versus paclitaxel alone.
Sensitivity Analysis
We performed a one-way sensitivity analysis to assess the effect of
different input parameters on the probability of FP and FN HER2 test
results. When available, we used the bounds of the 95% conﬁdence
intervals (CIs) as high and low estimates in the sensitivity analysis.
When the bounds of the 95% CIs were unavailable, we used a range
of 20% for probabilities and 50% for costs.Results
The results of this analysis are summarized in Table 2. In the total
population of patients with EBC, the individual patient probabilities
of FP or FN test results were found to be 3.12% and 2.18%,
respectively. Given an estimated 226,870 incident cases of EBC in
2012, the expected number of women whose tumors were mis-
classiﬁed as HER2-positive was estimated to be 7,070; the corre-
sponding value for tumors misclassiﬁed as HER2-negative was
4,955. A total of 8424 QALYs (discounted, lifetime) were lost because
of FN results (calculated as the number of patients with FN results
Fig. 1 – Decision-analytic model showing the potential results of HER2 testing in a patient with early-stage breast cancer (EBC),
including correct classiﬁcation (true positive [TP] and true negative [TN]) and misclassiﬁcation (false positive [FP] and false
negative [FN]). FISH, ﬂuorescence in situ hybridization; HER2, human epidermal growth factor 2; IHC, immunohistochemistry.
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trastuzumab vs. chemotherapy in patients with HER2-positive
breast cancer). The mean per-patient costs of FP and FN test results
were estimated to be $58,931 and $116,004, respectively. This would
result in aggregate national costs of $416 million owing to FP HER2
test results and $575 million owing to FN test results. Thus, under
the base case, the total lifetime aggregate cost of HER2 testing
inaccuracy in the United States would be $992 million.
After performing one-way sensitivity analyses, we found that
the aggregate national societal cost of HER2 testing inaccuracy
was most sensitive to changes in the following variables: 1)
QALYs gained for patients on trastuzumab (range 7.4–14.1)
changed the aggregate national societal cost of HER2 testing
inaccuracy from $300 million to $2.45 billion; 2) the QALYs for
patients not on trastuzumab (range 6.4–12.1) changed the aggre-
gate national societal cost of HER2 testing inaccuracy from $1.45
billion to $190 million; 3) the willingness to pay for an additional
QALY (range $50,000–$150,000) changed the aggregate national
societal cost of HER2 testing inaccuracy from $567 million to $1.42
billion; and 4) the speciﬁcity of FISH (range 0.76–1) changed the
aggregate national societal cost of HER2 testing inaccuracy from
$1.72 billion to $961 million.Discussion
We estimated the individual patient probability of obtaining FP or
FN HER2 test results to be 3.12% and 2.18%, respectively. The
likelihood of tumor misclassiﬁcation is affected by 1) the prevalence
of HER2 overexpression in the population; 2) the accuracy of the
HER2 testing method; and 3) the impact of reﬂex testing, deﬁned as
retesting an IHC 2þ tumor result with a FISH test. With regard tothe ﬁrst point, the exact proportion of patients in the general breast
cancer population with TP tumors is unknown. What is known is
that there are fewer patients with TP tumors than with TN tumors.
Consequently, models such as ours that consider both HER2-
positivity and HER2-negativity may be expected to yield a higher
probability of tumors being misclassiﬁed as HER2-positive rather
than HER2-negative because a test with a similar error rate for
detecting HER2-positive and HER2-negative tumors would, by
default, yield a higher proportion of FP test results because of the
larger number of patients whose tumors are HER2-negative.
The accuracy of HER2 testing methods has improved over the
years [17]. In the 2007 ASCO/CAP HER2 testing recommendations,
FP rates as high as 20% were reported, yet after the implementa-
tion of a quality assurance program, this rate fell to the range of
5.6% to 8.6% [18]. Both IHC and FISH tests, performed in accredited
laboratories, are considered acceptable. A prospective randomized
controlled trial comparing outcomes (e.g., disease recurrence and
overall survival) in patients with EBC whose tumors have been
tested using different HER2 testing algorithms (including reﬂex
testing) would be ideal, but is unlikely, due to feasibility issues.
In terms of the effect of reﬂex testing on the probability of
tumor misclassiﬁcation [19], patients with IHC 2þ tumors
(median of 12% of all IHC test results [20]) are reﬂex tested with
FISH. Reﬂex testing with FISH signiﬁcantly reduces the rate of a
tumor being misclassiﬁed as HER2-negative—and its associated
negative clinical implications—because, in our model, the FN rate
becomes the joint probability of a tumor being misclassiﬁed as
HER2-negative on both initial IHC testing and reﬂexive FISH
testing. The rate of HER2-positive misclassiﬁcation using IHC
testing is unaffected by reﬂex testing because all patients with
tumors categorized as HER2-positive (both TPs and FPs) are
treated. Of note, the baseline rates of FP and FN HER2 test results
Table 1 – Parameters used to inform the decision-analytic model.
Parameter Base case Low High Reference
Probabilities
True HER2-positive status 0.2 0.18 0.25 [2–5]
Initial test IHC (vs. FISH) 0.8 0.40 1.00 [20,27,28]
IHC performance [29]
Sensitivity 0.84 0.81 0.87
Speciﬁcity 0.96 0.95 0.96
FISH performance Assumption
Sensitivity 0.99 0.75 0.99
Speciﬁcity 0.99 0.85 0.99
Empirical distribution IHC results [20]*
IHC 0 0.36 0.18 0.54
IHC 1þ 0.36 0.18 0.54
IHC 2þ 0.12 0.06 0.18
IHC 3þ 0.16 0.08 0.24
Initial FISH test is þ 0.21 0.11 0.32 [20]*
FISH test þ after initial IHC2þ result 0.30 0.15 0.45 [20]*
Costs ($)
IHC test 134 102 166 [30]
FISH test 245 180 312 [30]
Trastuzumab 55,687 52,903 58,472 [14]
Cardiotoxicity treatment 2,200 1,100 3,918 [14]
Incremental cost of recurrence 3,931 3,735 4,128 [15]
Health outcomes
QALYs with trastuzumab (discounted, lifetime) 11.78 7.376 14.136 [14,25]
QALYs without trastuzumab (discounted, lifetime) 10.08 6.424 12.096 [14,25]
Disutility of cardiotoxicity 0.104 0.0084 0.0125 [18,31]
Incremental risk of cardiac event on trastuzumab 0.029 0.023 0.035 [16]
Willingness to pay for a QALY ($) 100,000 50,000 250,000 [32]
FISH, ﬂuorescence in situ hybridization; HER2, human epidermal growth factor 2; IHC, immunohistochemistry; QALY, quality-adjusted life-
year.
* Sensitivity range corresponds to 50% to incorporate substantial uncertainty in parameter estimate.
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probability of reﬂex testing, and are therefore higher than those
reported in our model. To further minimize the likelihood that
tumors will be misclassiﬁed, some analysts have argued that all
negative tumors, not just those with borderline scores, should be
retested [21].
In our analysis of the 2012 cohort of women newly diagnosed
with EBC, the aggregate economic costs of FP and FN test results
were $416 million and $575 million, respectively, for a combined
opportunity cost of almost $992 million. Thus, the small proba-
bility of a tumor being misclassiﬁed as HER2-negative, 2.2%,
results in a substantial expected aggregate cost of inaccuracy.
The “minimum feasible” aggregate cost of HER2 testing inaccur-
acy (i.e., near-perfect IHC [99% sensitivity; 99% speciﬁcity] and
FISH [99% sensitivity; 99% sensitivity]) and test implementation
would be approximately $166 million, compared with $992
million in our base case. This is attributable to the substantial
opportunity cost in terms of lost QALYs if even a single individual
with HER2-positive EBC is denied HER2-targeted therapy because
of HER2 testing limitations. A joint analysis of EBC trials of
patients with HER2-positive disease showed that 73.7% of the
patients not receiving HER2-targeted treatment were disease-free
at 4-year follow-up; however, among those receiving trastuzu-
mab, this proportion increased to 85.7%, representing a risk
reduction of about 46% [18]. Newer agents such as pertuzumab
have shown clinical beneﬁt in patients with HER2-positive meta-
static breast cancer [22,23] and are currently being tested in the
early-stage disease setting. Although we cannot yet accurately
predict which patients with HER2-positive EBC are most likely to
beneﬁt from HER2-targeted therapies, any improvements inpatient outcomes with new HER2-targeted therapies will increase
the costs associated with FN test results, thereby augmenting the
returns on improved HER2 testing diagnostics. According to our
analysis, an investment in improving HER2 testing accuracy
would yield substantial economic value—more than $700 million
for each annual cohort. Although newer, potentially more accu-
rate HER2 tests, mostly based on in situ hybridization, continue
to emerge, research is needed to determine the potential costs
and feasibility of these new testing strategies.
The magnitude of the monetized QALY loss due to HER2
testing inaccuracy is dependent on the estimate of QALYs gained
because of trastuzumab therapy as estimated in the study by
Garrison et al. [14] and its underlying assumptions. Other studies
suggest that the magnitude of this QALY gain is lower [24,25]; we
included these estimates in sensitivity analyses. In addition, the
study by Garrison et al. used data from a joint analysis of trials B-
31 and N9831 that may have included some patients whose
tumors were FP [26]. Consequently, this study likely underesti-
mates the economic impact of testing inaccuracy.
One limitation of this analysis is that it is descriptive in
nature. It provides a quantitative estimate of the relative oppor-
tunity and opportunity cost of tumor misclassiﬁcation, but it does
not indicate what can or should be done to remedy FP and FN test
results and efﬁciently reduce opportunity cost. Moreover, our
model does not consider the 2013 ASCO/CAP HER2 testing
recommendations, in which dual-probe in situ hybridization–
tested tumors with a HER2:CEP17 ratio of less than 2 can be
considered positive, negative, or equivocal (or the resulting reﬂex
testing patterns and outcomes) [19]. The 2013 ASCO/CAP HER2
testing recommendations are anticipated to reduce the burden of
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 4 1 – 5 4 6 545tumor misclassiﬁcation, at least to some extent. Provided that the
appropriate data on HER2 diagnostics in the clinical practice
setting become available, future studies can examine this issue
in relation to the base case established in the present analysis.
Until such time, this study conﬁrms that in terms of both clinical
outcomes and opportunity costs (at both the individual and
societal levels), FN HER2 test results have greater health con-
sequences than do FP test results. In light of the almost $1 billion
estimated annual burden associated with FP and FN test results,
substantial investments in improving HER2 testing accuracy
should be considered.
Source of ﬁnancial support: Genentech, Inc., supported
this study.
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